News

Gatekeeper to cancer senescence
Enlarge image

ResearchNetherlandsSpainBelgiumUK

Gatekeeper to cancer senescence

21.05.2013 - Dutch cancer experts have found an enzyme that seems to induce cancer senescence.

When oncogenes are activated inside a cell, they normally mobilise tumour suppressor networks which can act like a brake to cancer through a process termed oncogene-induced senescence (OIS). They withdraw proliferating cells almost irreversibly, providing protection against malignant transformation. Now, a research team led by Daniel Peeper from the Netherland’s Cancer Institute in Amsterdam has identified a metabolic gate-keeper of the process. 

Using metabolic and functional analyses of melanoma cells carrying the common BRAFV600E mutation, the team of Dutch, Scottish, Belgian, Spanish, Israeli and US researchers identified the TCA enzyme pyruvate dehydrogenase  (PDH) as a crucial mediator of cancer senescence. BRAFV600E-induced senescence was accompanied by simultaneous  suppression of the PDH-inhibitory enzyme pyruvate dehydrogenase kinase 1 (PDK1) and induction of the PDH-activating enzyme pyruvate dehydrogenase phosphatase 2 (PDP2). The resulting combined activation of PDH enhanced the use of pyruvate in the tricarboxylic acid cycle, causing increased respiration and redox stress. 

Enforced normalisation of either PDK1 or PDP2 expression levels inhibited PDH and abrogated oncogene-induced senescence. Depletion of PDK1 eradicated melanoma subpopulations resistant to targeted BRAF inhibition, and caused regression of established melanomas. The results suggest a mechanistically new therapeutic route to induce cancer senescence and stop tumour cell proliferation at its earliest stages.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/metabolic-gatekeeper-to-cancer-senescence.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products